Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 25, 2018 (8 years ago)

Dymista (azelastine hydrochloride and fluticasone propionate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of foreign substance: Potential for glass in the neck area of the glass bottles.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137 mcg / 50 mcg per spray, packaged in a 23 g net fill weight, Rx only, Manufactured by: Cipla Ltd., Goa, India, M.L.,, NDC 0037-0245-23

Affected NDC 0037-0245-23

Compare with the code on your package — it is the most precise check available.

Drug: Fluticasone Category: Allergy & Cold Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dymista
Azelastine Hydrochloride and Fluticasone Propionate
NDC 00037-0245
AZELASTINE HYDROCHLORIDE 137 ug/1; FLUTICASONE PROPIONATE 50 ug/1 Spray, Metered
Nasal
Viatris Specialty LLC Rx
Recalling firm
Mylan Pharmaceuticals Inc.
NDC code
0037-0245-23
Origin
WV, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1075-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Fluticasone recalls

See all
Class II · Moderate risk

Inhub Wixela

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0202-2024

Other recalls by Mylan Pharmaceuticals Inc.

All 2018 recalls
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

Ongoing Dissolution failure Mylan Pharmaceuticals Inc NDC 0378-5186-93 D-0839-2026